BI Asset Management Fondsmaeglerselskab A S Purchases 16,568 Shares of Becton, Dickinson and Company $BDX

BI Asset Management Fondsmaeglerselskab A S boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 96.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 33,694 shares of the medical instruments supplier’s stock after acquiring an additional 16,568 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Becton, Dickinson and Company were worth $7,718,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legacy Financial Advisors Inc. raised its stake in Becton, Dickinson and Company by 19.2% in the 1st quarter. Legacy Financial Advisors Inc. now owns 1,132 shares of the medical instruments supplier’s stock valued at $259,000 after acquiring an additional 182 shares during the period. Hsbc Holdings PLC raised its stake in Becton, Dickinson and Company by 0.6% in the 1st quarter. Hsbc Holdings PLC now owns 661,269 shares of the medical instruments supplier’s stock valued at $151,189,000 after acquiring an additional 4,155 shares during the period. HC Advisors LLC bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $229,000. Aptus Capital Advisors LLC raised its stake in Becton, Dickinson and Company by 6.8% in the 1st quarter. Aptus Capital Advisors LLC now owns 14,651 shares of the medical instruments supplier’s stock valued at $3,356,000 after acquiring an additional 927 shares during the period. Finally, Aviso Financial Inc. raised its stake in Becton, Dickinson and Company by 7.7% in the 1st quarter. Aviso Financial Inc. now owns 21,558 shares of the medical instruments supplier’s stock valued at $4,938,000 after acquiring an additional 1,538 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BDX. Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Citigroup cut Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and decreased their price target for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. William Blair cut Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Stock Up 1.5%

Shares of NYSE BDX opened at $197.8470 on Wednesday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $56.71 billion, a price-to-earnings ratio of 35.58, a PEG ratio of 1.46 and a beta of 0.20. The business has a 50-day moving average of $179.13 and a 200-day moving average of $196.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president directly owned 4,575 shares of the company’s stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,214 shares of company stock valued at $579,206. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.